we Thanks, for joining our thanks as today share XXXX everyone on update Tracy results discuss the business. quarter us and and second an
the pandemic. We challenges are given second the significant quarter pleased from results COVID-XX our with
$XX.X this million, had $XX.X of we revenue was the revenue testing total which Our and given anticipated is the included million, better than product decline XX% pandemic.
in test was quarter Our over the susceptible at see physicians some We open. and hospitals an more marking last as begin volume biopharmaceutical strong revenue, procedures regionally was increase to during the year. began impacts uptick COVID-XX other XX% a partnership and million, the to which non-emergency $X.X began to same quarter conducting less
genomic doubled to testing in June April. volume our we fact, compared In
volumes and XXXX. believe year early in prior our and closely determine ordering trend a with test our still continue. are will expect this to tracking We recovery status that, to U-shaped return We customer practices to onefold, whether will levels
on volume testing evidence advancement. will our like time. business, the which I turn we and would provide Given a I pipeline with not progress to guidance second development the results revenue, XXXX are core highlights our fluid product at and state beginning of quarter to this then our includes pandemic, now and partnerships. strategic updating and our
slightly higher from was revenue the pandemic. testing than product Our our expectations and
Our screening testing and found. of funnel surgeries, our number through a scans which before potential year. June. patients This procedures from the visits, reduced tests saw elective XX% be cancer imaging for rebound entering decline quarter other of $XX.X We a would was second revenue last reflects noted the via million, the routine doctor in
to However, samples. double may total that pulmonology the of rebound performed that genomic where to portfolio would anticipated Afirma of had and franchise volume be the April. our nature given slower be obtain patient was We correctly to first the our procedures continue believe
Prosigna understanding business, recognition breast revenue that in On decision-making and disease $X.X and which the testing test biological clinical growing the information the revenue, subtype nCounter-related from a growing cancer We the was million, believe built around was encompasses Prosigna the exceeded increased of Prosigna internal expectations. product subtypes. side our of in stems intrinsic which interest of our utility these treatment
We also key guide future growth globally. this the believe information will of product
growing Zealand. purposes and and business, support nCounter will system our we have through for System the throughout New diagnostic as Pacific global on tests menu growing Australia to as Additionally, our agreements in to of offer the Asia which signed hospitals and laboratories distributor we well
of continue to for test. reimbursement portfolio, evidence We our library our commercial the clinical across driving expand to key which is
Classifier in American confidently This derived follows idiopathic morning, and high-resolution results announced expand that interstitial lung the of and the data independent when to not were Classifier pulmonary Critical without prospective need previously showing fibrosis also from The at BRAVE which University, findings IPF were ability Tulane researchers physicians from Care improves we imaging Medicine reported data of surgery. physician’s this Envisia from the the CT to in validation definitive. the recent Respiratory and multi-center Just clinical showing Journal diagnose publication publication diseases and appear the our the new Genomic for results, CHEST more diagnose other of trials. Envisia confirm enabled that
Further, targeted relates further of laboratory Society, and core the franchise development diagnostic precision evaluated medicine Afirma in showcased journey. the our our ability a X growth care that pipeline building patient faster, published in novel to upon the leading efficient, business, accelerating is strength number pulmonology touch the early of Atlas this help as approved reach and growth. drive and to genomic gene genomic cancer industry-leading will American the data to for Afirma decisions NTRK article other information positions Cancer the track in than Our the advance our care more continuum. more in decisions of indication therapy in it journal of Cancer test our in review Eli a continued market treatment thyroid and a guide this Atlas. and to endocrinologists remain Last, and tests in for that of XXXX, is on Bayer’s such perfectly We provide thyroid targeting the comprehensive patient that position us as inform of nation fusions Xpression drug. lung important built plans information, and tests the is providing this RET-targeted space advance continues to of the cancer We believe generation aim becoming cancer. Lilly/Loxo Xpression the patients therapies any are expected we grow, development launch the in clinical for portfolio with throughout in to as and publication an cancer that to core important for to This treatment more Oncology’s Cytopathology, thyroid increasingly being more
during fact expect launch next in lung two of half year. the cancer new tests second to in We
costly, saves treatment and early cancer procedures. will we exceeds swab The lives out date. tremendous swab. people increase lung We stratifying for diagnosis harmful likely Services nasal the nasal and An value be the the low-dose of lung Force our cancerous based our would to unnecessary today could nearly rule we’ve recommendations billion, on patients. here, that cancer by Both the eligible significantly, First, for the TAM TAMs promises as very launched cancer accurate screening. that double often is diagnostic Preventive nasal nodules number in which the products are will CT that spare approximately can both provide patients classifier of noninvasive test who inefficient benign to given current advance can a estimate Task factors to far with U.S. TAM clinical be $X earlier swab simple important course, from patients recent invasive also an risky annual of early or and process and test
first Percepta panels offered the on treatment help biopsy our Atlas based gene profiling the in that alteration time transcriptome genomic at assay, Second test a whole We a is and comprehensive inform test the this profiling time it the small believe is cancer lung will far of using on the diagnosis for decisions sample. making marketplace with right than sequencing other today. patients comprehensive more
diagnostic the to stage later. lung part the workup Our genomic afterthought, intent an cancer of diagnosed as is and type XX information every as of to improve for not days dramatically XX available
every insights is late-stage stage information transcripts on biological will today, information primarily cancers. for based Atlas early We whereas us also with cancer Percepta the This fuel cancer first development the stages downstream XXX,XXX transcriptome for of that medicine could enable therapies captures all over perhaps data whole to on potentially of biorepository X, precision X believe through sample. and for build such help cancer, of focused recurrent the lung
nCounter year other diagnosis We improved the platform diseases, expansion. or Envisia interstitial idiopathic are and also international of test excited lung pulmonary next our the fibrosis on launch about for of Classifier the ILDs,
in interested Envisia part thought the dozen engaging key on our which becoming for already at program board expect early Europe XXXX. of in late are sites of who have expected commercial and launch, is leaders are We very to access over a ILD across time
Europe country there. preparation We management and positions are to hiring market in also marketing advance key our work
year for with we of fourth for De to lymphoma June, Novo disease management FDA LymphMark test a diffuse support Our to the large use newly test. request for subtyping classification our test is B-cell patients the diagnosed lymphoma. next submitted In launch
the We platform. in who using targeted for from like receiving in businesses product requests nCounter XXXX. of to would access specialty This service is introduction laboratories first the their half are already inbound LymphMark
among to with to pandemic and moving share last I’d the quarter, new collaboration to the customers of business, steps two are the we our virtually. customers engage other to opportunities which of strategic campaigns our tactics. significant less taking seize Before In we included e-mail the accessible like interest technology, speaker with holding over our some nationwide, ramped side to customers use digital that virtual programs garnered due dozen
also digital are relevant deepen sales piloting in and We understanding medicine our our format. strengthen strategies of a the ways significant see customer bring opportunity their to personalized to timely, We tests a to value our customers efficiencies, information further engagement. precision digital and to we as we in evolving organization our our relationships an additional scaled increase utilize believe approximately that are business we are drive more through sales we’ve to efficient with models appropriately advance landscape. believe for and growth these with will XXXX ensure which In continues decisions. We tandem, as eliminated positions XX rebound we to positioned physician operating
tests and of Let’s partnerships, turn testing lymphoma second information leveraging partnerships year a over important proprietary the have our and challenging $X.X granted diagnostic under generated on This to each thyroid unearth, also Oncology, only to development J&J biological from the revenue in with here row It biopharma We revenue AstraZeneca that with highly biopharmaceutical LymphMark lever of our includes from biopharma fees the be recognized Pharma, commercial collecting during we’ve would and for rely a test; Acerta cancer; company. insights partner. for making our which been sub-typing rates agreement. partners test; to payments achievements our value creation Lilly otherwise. our in milestone upfront genomic our million Innovation QX, differentiated is to clinical our we in profitable progress related provide note nasal on years this and in but Loxo swab which supply our not the that quarter first Eli diagnostic and and CareDx testing to our for to
menu, that to on we we secured the the one would entire platform. tests revenue-generating the providing when This partnering companies develop the the with for attractiveness System, diagnostic us. for Additionally, global of rights was opportunities additional avenue nCounter while to their exclusive other determined enhance growth
and influenza through announced to the playing use and right in on testing payments. require X to venues System. thesis This with MAVIDx potentially led two testing clinical We setting, highly This acquisition scale be QX that workplaces, for test through of enable would the System. and throughput samples processed partnership MAVIDx technology, agreement we include We nCounter COVID-XX virus inventor MAVIDx week, an is the transplantation; COVID-XX address milestone and nCounter novel results million excited generate multiplexed barcode the potential System. sales, Earlier was other founder sales Dimitrov, for our significant track the and continue and to to the and plans be delivered ultra-high partnership and tests to revenue who XX,XXX granted testing. CareDx COVID-XX nCounter beyond other partners, global announced System. develop organ to on May MAVIDx’s and frequent to day simplicity nCounter Dr. the for in will our this NanoString solid we configuration on in an for that and has available see nCounter $X the Krassen would the effort with to which contain the now enable widely exciting infectious massive need through develop schools additional molecule diseases. CareDx an the of over in transplant kit which with assay by great diseases other which patient in assessed technology and powers single through exclusive CareDx are to MAVIDx We a allows out believe infectious
secured nCounter and instruments MAVIDx any and have for supply that an commercializes. the test stake company equity in and kits We will develops test
companies in U.S. key expertise Financial stage results, which Directors, picks X, global Germany. financial for company wide global Jim and an recent of team, and us our join our Chief Counsel wealth expansion. also a Executive up Vice of joined to experience clinical of biopharmaceutical Veracyte a of of management highlight for global Keith the the markets. vision will and health MorphoSys, life science Board has I help to Erlinger based our Secretary, achieve care wanted bringing with range is the addition Holstein Jens as He in will financial And to Before President, General Veracyte bringing company. the August a the legal talent Officer and
a call thrilled of them to quarter review the XXXX to family. second our Keith welcome to more the are over I will for We both Veracyte now turn detailed financials.
